Compare Stocks

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGTC Applied Genetic Technologies	$0.39	$0.39	$0.23 ▼ $2.83	$26.62M	1.55	943,490 shs	N/A
CSBR Champions Oncology	$5.06 -0.2%	$10.15	$7.19 ▼ $14.68	$68.77M	0.39	2,940 shs	960 shs
GMDA Gamida Cell	$0.02	$0.24	$0.03 ▼ $2.51	$2.56M	0.93	9.20 million shs	1.72 million shs
OTLK Outlook Therapeutics	$8.17 -1.4%	$8.61	$4.00 ▼ $40.60	$106.29M	0.04	547,081 shs	271,754 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGTC Applied Genetic Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
CSBR Champions Oncology	+0.70%	+1.91%	-0.69%	-24.40%	-3.71%
GMDA Gamida Cell	-8.24%	+24.80%	-95.99%	-94.88%	-99.03%
OTLK Outlook Therapeutics	-3.72%	-8.30%	+11.95%	+18.77%	-63.96%

The only accurate crypto trading system I know … (Ad)

Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.

Here's what our expert says you should buy before April 14.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGTC Applied Genetic Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CSBR Champions Oncology	3.7133 of 5 stars	3.3	4.0	0.0	4.6	0.6	2.5	0.0
GMDA Gamida Cell	0.599 of 5 stars	3.4	2.0	0.0	0.0	0.0	0.8	0.0
OTLK Outlook Therapeutics	3.0118 of 5 stars	4.4	2.0	0.0	0.0	2.9	1.7	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGTC Applied Genetic Technologies	N/A	N/A	N/A	N/A
CSBR Champions Oncology	2.50	Moderate Buy	$7.50	48.22% Upside
GMDA Gamida Cell	2.75	Moderate Buy	$4.75	28,514.46% Upside
OTLK Outlook Therapeutics	2.88	Moderate Buy	$46.43	468.24% Upside

Current Analyst Ratings

Latest OTLK, CSBR, GMDA, and AGTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2024	OTLK Outlook Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
3/25/2024	OTLK Outlook Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00
3/13/2024	CSBR Champions Oncology	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
2/16/2024	OTLK Outlook Therapeutics	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight
2/15/2024	OTLK Outlook Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$60.00
1/29/2024	GMDA Gamida Cell	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
1/25/2024	OTLK Outlook Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$31.40
1/25/2024	OTLK Outlook Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$40.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGTC Applied Genetic Technologies	$320K	83.19	N/A	N/A	$0.26 per share	1.51
CSBR Champions Oncology	$53.87M	1.28	N/A	N/A	$0.34 per share	14.88
GMDA Gamida Cell	$1.78M	1.43	N/A	N/A	($0.02) per share	-0.83
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	($1.11) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGTC Applied Genetic Technologies	-$68.94M	-$1.46	N/A	N/A	N/A	N/A	-192.90%	-92.54%	N/A
CSBR Champions Oncology	-$5.34M	-$0.72	N/A	∞	N/A	-19.76%	-850.72%	-32.62%	7/22/2024 (Estimated)
GMDA Gamida Cell	-$63M	-$0.63	N/A	∞	N/A	N/A	N/A	-57.59%	5/20/2024 (Estimated)
OTLK Outlook Therapeutics	-$58.98M	-$4.00	N/A	N/A	N/A	N/A	-3,741.39%	-132.37%	5/20/2024 (Estimated)

Latest OTLK, CSBR, GMDA, and AGTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q3 2024	CSBR Champions Oncology	N/A	-$0.19	-$0.19	-$0.19	N/A	$12.02 million
2/14/2024	Q1 2024	OTLK Outlook Therapeutics	-$1.00	-$0.80	+$0.20	-$0.04	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGTC Applied Genetic Technologies	N/A	N/A	N/A	N/A	N/A
CSBR Champions Oncology	N/A	N/A	N/A	N/A	N/A
GMDA Gamida Cell	N/A	N/A	N/A	N/A	N/A
OTLK Outlook Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGTC Applied Genetic Technologies	0.39	1.40	1.40
CSBR Champions Oncology	N/A	0.60	0.60
GMDA Gamida Cell	213.14	2.16	2.09
OTLK Outlook Therapeutics	N/A	0.44	0.44

Ownership

Institutional Ownership

Company	Institutional Ownership
AGTC Applied Genetic Technologies	22.05%
CSBR Champions Oncology	41.30%
GMDA Gamida Cell	50.34%
OTLK Outlook Therapeutics	11.20%

Insider Ownership

Company	Insider Ownership
AGTC Applied Genetic Technologies	4.10%
CSBR Champions Oncology	45.69%
GMDA Gamida Cell	3.40%
OTLK Outlook Therapeutics	5.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AGTC Applied Genetic Technologies	83	67.63 million	64.86 million	Optionable
CSBR Champions Oncology	143	13.59 million	7.38 million	Optionable
GMDA Gamida Cell	143	154.05 million	143.70 million	Optionable
OTLK Outlook Therapeutics	24	13.01 million	12.32 million	Optionable

OTLK, CSBR, GMDA, and AGTC Headlines

Source	Headline
	World Economic Outlook: IMF revises GDP predictions for LATAM and the Carribbean invezz.com - April 18 at 6:25 PM
	World Polyethylene High Density (HDPE) Market Outlook 2024-2033: Capacities, Production, Consumption, Trade Statistics, and Prices finance.yahoo.com - April 18 at 6:25 PM
	Economic Outlook 2024 in Springfield connectionnewspapers.com - April 18 at 6:25 PM
	Bosch Flags Further Cost Cuts After Giving 'Subdued' Outlook for 2024 usnews.com - April 18 at 6:25 PM
	Reporter's Guarentee \| Outlook's Rakhi Bose In Conversation With Dalit Villagers In Saharanpur District outlookindia.com - April 18 at 6:25 PM
	Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million globenewswire.com - April 15 at 4:15 PM
	Biotech on a Budget: 7 Stocks Under $10 With Huge Potential investorplace.com - April 15 at 12:54 PM
	Outlook Therapeutics (NASDAQ:OTLK) versus Vigil Neuroscience (NASDAQ:VIGL) Head-To-Head Contrast americanbankingnews.com - April 15 at 1:14 AM
	US Consumer Sentiment Falls Slightly as Outlook for Inflation Worsens msn.com - April 14 at 9:03 AM
	Microsoft Outlook 2010's Default Profile Pic Was Based on Bill Gates' 1977 Mug Shot? msn.com - April 14 at 9:03 AM
	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts americanbankingnews.com - April 13 at 4:32 AM
	Fed's Williams: Outlook is uncertain, Fed must be data-dependent fxstreet.com - April 11 at 6:05 PM
	National Gas’ Summer Outlook 2024: Stable supply, reduced exports energylivenews.com - April 11 at 6:05 PM
	ADB Outlook forecasts 7 % GDP growth in 2025 bbs.bt - April 11 at 6:05 PM
	Natural Gas Price Forecast: Moving Average Breakout Improves Bullish Outlook fxempire.com - April 11 at 1:44 AM
	Stock Market Today: Wall Street Falls After Hot Inflation Data Burns Hopes for a June Rate Cut msn.com - April 11 at 1:44 AM
	Bitdefender now has identity protection for Gmail and Outlook msn.com - April 11 at 1:44 AM
	Insiders are Piling into These 10 Healthcare Stocks in 2024 finance.yahoo.com - April 10 at 3:44 PM
	Users Complain Gmail Blocks Email From Microsoft Outlook—Here’s The Fix forbes.com - April 3 at 3:14 PM
	Outlook.com trips over Google's spam blocking rules msn.com - April 3 at 3:14 PM
	Yezan Munther Haddadin Purchases 1,882 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) Stock insidertrades.com - March 30 at 7:48 AM
	BTIG upgrades Outlook Therapeutics stock to buy, cites ONS-5010 success uk.investing.com - March 29 at 8:32 PM
	Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin Acquires 1,882 Shares marketbeat.com - March 29 at 12:10 PM
	Outlook from the C-Suite: Freeman and GES Leaders Share Their Biggest Business Concerns tsnn.com - March 29 at 10:26 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Applied Genetic Technologies

NASDAQ:AGTC

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Champions Oncology

NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Gamida Cell

NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

Outlook Therapeutics

NASDAQ:OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial